Le Lézard
Classified in: Health
Subject: CCA

Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2019 Results Presentation and Webcast


OSLO, Norway, Aug. 16, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that it will report its results for the second quarter and first half 2019 on Thursday, 22 August 2019.

A presentation by Nordic Nanovector's senior management team will take place at 8:30am CEST at:

Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: AKER

The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investors & Media

The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2019 from 7:00am CEST the same day.

For further information, please contact: 

IR enquiries

Malene Brondberg
VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com  

Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: nordicnanovector@citigatedewerogerson.com  

About Nordic Nanovector: 

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act. 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--invitation-to-second-quarter-and-first-half-2019-results-presentation-and-web,c2882117

SOURCE Nordic Nanovector


These press releases may also interest you

at 03:00
COVID-19 has accelerated the need for food companies to build more resilient and transparent supply chains to cope with the challenges from an ever evolving marketplace. It is now more urgent than ever to have the proper framework that would allow...

at 03:00
The list of reviewed and approved NJ Top Docs at Kayal Orthopaedic Center, PC is continuously growing. Kayal Orthopaedic Center is home to an elite team of surgeons who are fully committed to skillful, restorative patient care. Patients in Franklin...

at 03:00
HashCash Consultants has partnered with a leading manufacturer in the US to help them streamline and facilitate the production and supply of PPE kits across various channels to keep unsaturated availability in the market. In the wake of the pandemic,...

at 02:51
Isofol Medical AB (publ) ("Isofol"), has today announced that it entered into a license agreement with Solasia Pharma K.K ("Solasia") (TSE: 4597), to develop and commercialize Isofol's proprietary late-stage drug candidate arfolitixorin in Japan. In...

at 02:44
Isofol Medical AB (publ) ("Isofol"), today announced that it entered into a license agreement with Solasia Pharma K.K ("Solasia") (TSE: 4597), a specialized oncology company headquartered in Japan, to develop and commercialize Isofol's proprietary...

at 02:16
Immunovia invites to a teleconference (in English) for investors, analysts and media on Thursday, August 20th, 2020 at 16:30 CET. Immunovia will publish the company's interim report on August 20th, 2020 at 16:00 CET. Mats Grahn, CEO will present...



News published on 16 august 2019 at 02:14 and distributed by: